Disc Medicine, Inc.
For the period ended Mar 31, 2025. Filed May 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 7, 2025
IRON$84.64+4.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities | ||
| Net loss | $(34,085) | $(26,949) |
| Adjustments to reconcile net loss to net cash used in operations: | ||
| Depreciation and amortization | 20 | 26 |
| Stock-based compensation | 6,363 | 4,058 |
| Amortization/accretion of investment securities | (2,527) | — |
| Non-cash lease expense | 112 | 142 |
| Non-cash interest expense | 207 | — |
| Other non-cash items | 15 | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (7,230) | (4,112) |
| Accounts payable | (1,277) | (7,360) |
| Accrued external research and development expenses | 280 | 3,763 |
| Other accrued expenses | (3,689) | (3,092) |
| Operating lease liabilities | 435 | (75) |
| Net cash used in operating activities | (41,376) | (33,599) |
| Cash flows from investing activities | ||
| Purchases of marketable securities | (347,250) | — |
| Maturities of marketable securities | 75,468 | — |
| Purchases of property and equipment | (851) | (67) |
| Net cash used in investing activities | (272,633) | (67) |
| Cash flows from financing activities | ||
| Proceeds from sale of common stock in underwritten offering, net of issuance costs paid | 234,003 | — |
| Proceeds from sale of pre-funded warrants in underwritten offering, net of issuance costs paid | 9,386 | — |
| Proceeds from sale of common stock in at-the-market offerings, net of issuance costs paid | — | 14,849 |
| Proceeds from stock option exercises | 575 | 806 |
| Contributions from employee stock purchase plan | 287 | 245 |
| Net cash provided by financing activities | 244,251 | 15,900 |
| Net decrease in cash, cash equivalents and restricted cash | (69,758) | (17,766) |
| Cash, cash equivalents and restricted cash, beginning of period | 192,672 | 360,616 |
| Cash, cash equivalents and restricted cash, end of period | $122,914 | $342,850 |
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Supplemental cash flow information | ||
| Cash paid for interest | $698 | $— |
| Supplemental disclosure of non-cash activities | ||
| Deferred issuance costs related to underwritten offering included in accounts payable and accrued expenses | $225 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.